# Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

> **NCT04386746** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 27 (actual)

## Conditions studied

- Urothelial Carcinoma Bladder
- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04386746
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2022-10-04
- **Final completion:** 2026-11-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04386746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04386746, "Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04386746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*